EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access · CC BY 4.0

A phase I study of liposomal Irinotecan (ONIVYDE®) in combination with TAS-102 (LONSURF®) in refractory solid tumors

Nai-Jung Chiang, Li-Yuan Bai, I-Wei Ho, Chih-Hung Hsu, Yi-Hsin Liang, Chang-Fang Chiu, Ching-Chan Lin, Kwang-Yu Chang, Shang-Hung Chen, Hui-Jen Tsai, Yu-Ping Lin, Li-Tzong Chen und 1 weitere

Investigational New Drugs · 2025-06 · 43 (3) · 709-718

DOI: 10.1007/s10637-025-01547-2 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Investigational New Drugs, online erschienen am 04.06.2025. Verfasst von Nai-Jung Chiang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Irinotecan, Trifluridine, Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PharmaEngine, Inc., Taiho Parma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Onivyde, a liposome-encapsulated irinotecan, is used for advanced pancreatic, while TAS-102 (trifluridine/tipiracil) is indicated for metastatic colorectal and gastric cancers. This study aims to determine the maximum tolerated dose (MTD), recommended phase II dose (RP2D), and safety profiles of liposomal irinotecan combined with TAS-102. This multicenter, phase I study utilized a 3 + 3 dose-escalation design. Patients with treatment-refractory solid malignancies received free base liposomal irinotecan at 50–70 mg/m 2 on Day 1 and TAS-102 at 25–35 mg/m 2 twice daily on Days 1–5 of a 14-day cycle. Patients homozygous for UGT1A1*28 (TA7/TA7) , UGT1A1*6 (A/A) , or double heterozygous ( TA6/TA7 and G/A ) alleles were excluded. Prophylactic G-CSF was allowed. Twenty-six evaluable patients were enrolled across seven dose levels of liposomal irinotecan (free-base)/TAS-102 combination: 3 patients each at level 1 (50/25 mg/m 2 ), level 2A (60/25 mg/m 2 ), level 2B (50/30 mg/m 2 ), and level 3 (60/30 mg/m 2 ); 6 at level 4A (70/30 mg/m 2 ); 3 at level 4B (60/35 mg/m 2 ); and 5 at level 5 (70/35 mg/m 2 ). An additional 15 patients were enrolled in the expansion cohort at the MTD of 70/30 mg/m 2 (level 4A), designated as the RP2D. Overall grade 3–4 treatment-related adverse events occurred in 44.2% of 43 all treated patients, with neutropenia (16.3%), diarrhea (14%), and fatigue (11.6%). Partial responses were observed in 18.4% of patients, predominantly in neuroendocrine tumor, gastric and esophageal carcinomas. The combination of liposomal irinotecan and TAS-102 at the RP2D of 70/30 mg/m 2 demonstrated acceptable safety and promising efficacy in refractory solid tumors, warranting further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IrinotecanTrifluridineNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsUracilHumansMaleMiddle AgedFemaleAgedDrug CombinationsLiposomesPyrrolidinesMaximum Tolerated DoseAdultThymine

Stichwörter der Autor:innen

EfficacyLiposomal irinotecanPharmacokineticsPhase 1 clinical trialSolid tumorsTAS-102

Substanzen

Irinotecantrifluridine tipiracil drug combinationTrifluridineDrug CombinationsLiposomesUracilPyrrolidinesThymine

Autor:innen und Institutionen

  • Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.
  • School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan.
  • Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital and China Medical University, Taichung, Taiwan.
  • Departments of Oncology, College of Medicine, National Taiwan University Hospital and Graduate Institute of Oncology, National Taiwan University, Zhongshan S. Rd, Taipei, 10002, Taiwan.
  • Department of Oncology, College of Medicine, National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan.

Förderung

  • PharmaEngine, Inc.
  • Taiho Parma

Zitieren

APA

Chiang, N. J., Bai, L. Y., Ho, I. W., Hsu, C. H., Liang, Y. H., Chiu, C. F., Lin, C. C., Chang, K. Y., Chen, S. H., Tsai, H. J., Lin, Y. P., Chen, L. T., & Lin, C. C. (2025). A phase I study of liposomal Irinotecan (ONIVYDE®) in combination with TAS-102 (LONSURF®) in refractory solid tumors. Investigational New Drugs, 43(3), 709-718. https://doi.org/10.1007/s10637-025-01547-2

Vancouver

Chiang NJ, Bai LY, Ho IW, Hsu CH, Liang YH, Chiu CF, et al. A phase I study of liposomal Irinotecan (ONIVYDE®) in combination with TAS-102 (LONSURF®) in refractory solid tumors. Investigational New Drugs. 2025;43(3):709-718. doi:10.1007/s10637-025-01547-2

BibTeX
@article{Chiang2025,
  author = {Chiang, Nai-Jung and Bai, Li-Yuan and Ho, I-Wei and Hsu, Chih-Hung and Liang, Yi-Hsin and Chiu, Chang-Fang and Lin, Ching-Chan and Chang, Kwang-Yu and Chen, Shang-Hung and Tsai, Hui-Jen and Lin, Yu-Ping and Chen, Li-Tzong and Lin, Chia-Chi},
  title = {A phase I study of liposomal Irinotecan (ONIVYDE®) in combination with TAS-102 (LONSURF®) in refractory solid tumors},
  journal = {Investigational New Drugs},
  year = {2025},
  volume = {43},
  number = {3},
  pages = {709--718},
  doi = {10.1007/s10637-025-01547-2}
}
Kostenlos starten →